Glenmark Pharma appointed Alessandro Riva as the new US unit CEO

The leading pharmaceutical company Glenmark Pharma has appointed Alessandro Riva as CEO (Chief Executive Officer) of its new innovation company based in the US.

Rewa will take office from April 02. He is currently the Executive Vice President for Oncology Therapy and Cell Therapy for Jilid Sciences. 

Explain that on February 14 this year, the Board of Directors of Glenmark Pharma got clearance to separate their innovation business as a new company based in the US.

Alessandro has worked in many global companies, including Novartis, Rhône-Pauquen Rover and Aventis.

On the other hand, the shares of Glenmark Pharma in BSE opened at Rs 600.50 with a slight drop in the previous close level of Rs 603.45. After the weak start, shopping in the company’s shares has been seen. It is at Rs. 605.00 with an increase of Rs. 1.55 or 0.26%, at 11 o’clock in the morning. At this price, the company’s market capitalization is Rs 17,071.17 crores. In the last 52 weeks, the highest share of the company has been Rs 711.55 and the lowest level of Rs 483.60.

Indian Stock Market- Get profitable Equity, MCX Service, HNI & Currency Services with good call accuracy. BSE Sensex & Nifty50. Our market researchers track the share positions and give best call accuracy to customers.

Please follow and like us: